BRAF and cutaneous mastocytosis: This study randomized BRAF-mutant metastatic CM patients into three arms: encorafenib plus binimetinib followed by crossover to ipilimumab plus nivolumab upon disease progression, the inverse sequence, or a sandwich approach where induction with 8-weeks of encorafenib plus binimetinib was followed by ipilimumab plus nivolumab until disease progression, at which point targeted therapy was initiated again.